Date of report 26 Apr 2022

Reported case interaction between
Cobicistat and ERGOTAMINE

A 21-year-old man came to the emergency department for sudden onset of pain and paresthesias in both legs that had started 3 days earlier. His history included smoking 10 cigarettes per day, migraine occasionally treated with Migral® (ergotamine 1 mg, dipyrone 500 mg and caffeine 100 mg) and a recently diagnosed HIV infection on antiretroviral treatment elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide 150/150/200/10 mg per day. He had no previous symptoms of intermittent claudication, no history of rheumatic diseases, coagulopathies or drug abuse. Femoral pulses in both legs were present, but no popliteal, tibial or pedal pulses were detected on physical examination. He had digital hypoesthesia and preserved motor function. An echo-Doppler did not detect signal in the feet. Increased CPK (754Ul/mL) was observed. In an angio-CT scan the contrast was barely visible below the knee and did not reach below the ankle in both legs. Acute ischemia secondary to vasospasm was diagnosed. Ergotamine was discontinued and enoxaparin 60 mg sc bid plus prostaglandin E1 60 mcg iv qd, acetylsalicylic acid 100 mg vo qd and nifedipine 20 mg vo qd were started. After 48h, the patient reported no pain and partially recovered digital sensitivity. He was discharged with the same antiretroviral treatment, aspirin 100 mg vo qd, and enoxaparin 60 mg sc bid. Treatment with prostaglandin E1 60 mcg iv qd was maintained for 21 days. At one month follow-up he was asymptomatic. Treatment was suspended and the recommendation to avoid ergotamine derivatives together with his antiretroviral treatment with cobicistat was reinforced.

Hostench-Junoy N et al. describe the second case of ergotism secondary to interaction between ergotamine and cobicistat. (Hostench-Junoy N, et al. Acute Ischemia of Lower Extremities Caused by Ergotamine Toxicity due to Pharmacologic Interaction With Cobicistat in an HIV-Positive Patient. Ann Vasc Surg. 2022;80:392.e1-392.e6. doi:10.1016/j.avsg.2021.09.023)